Pastor Yadira, Ghazzaui Nour, Hammoudi Adele, Centlivre Mireille, Cardinaud Sylvain, Levy Yves
Vaccine Research Institute, Université Paris-Est Créteil, Institut Mondor de Recherche Biomédicale, Inserm U955, Team 16, Créteil, France.
Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service Immunologie Clinique, Créteil, France.
Front Immunol. 2022 Aug 9;13:949779. doi: 10.3389/fimmu.2022.949779. eCollection 2022.
The development of safe, long-term, effective vaccines is still a challenge for many infectious diseases. Thus, the search of new vaccine strategies and production platforms that allow rapidly and effectively responding against emerging or reemerging pathogens has become a priority in the last years. Targeting the antigens directly to dendritic cells (DCs) has emerged as a new approach to enhance the immune response after vaccination. This strategy is based on the fusion of the antigens of choice to monoclonal antibodies directed against specific DC surface receptors such as CD40. Since time is essential, approaches are of high interest to select the most immunogenic and conserved epitopes to improve the T- and B-cells responses. The purpose of this review is to present the advances in DC vaccination, with special focus on DC targeting vaccines and epitope mapping strategies and provide a new framework for improving vaccine responses against infectious diseases.
对于许多传染病而言，研发安全、长效、有效的疫苗仍是一项挑战。因此，寻找能够快速有效应对新出现或再次出现病原体的新疫苗策略和生产平台，在过去几年已成为当务之急。将抗原直接靶向树突状细胞（DCs）已成为一种增强疫苗接种后免疫反应的新方法。该策略基于将所选抗原与针对特定DC表面受体（如CD40）的单克隆抗体融合。由于时间至关重要，因此选择最具免疫原性和保守性的表位以改善T细胞和B细胞反应的方法备受关注。本综述的目的是介绍DC疫苗接种的进展，特别关注DC靶向疫苗和表位作图策略，并为改善针对传染病的疫苗反应提供一个新框架。
